Evidence map›Paper›PMID 40820676›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

High-throughput virtual screening, identification and

Yang Xia, Yuting Chang, Lixia Guan, Yifei Geng, Qi Zhang, Xiaozhou Shen, Qian Bu, Miao-Miao Niu, Gaohua Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yang XiaDepartment of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Yuting ChangDepartment of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Lixia GuanDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Yifei GengDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Qi ZhangDepartment of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Xiaozhou ShenDepartment of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Qian BuDepartment of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Miao-Miao NiuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Gaohua HanDepartment of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overexpression of PLK1 and NRP1 correlate with enhanced proliferative activity in lung cancer cells, thus the development of dual-target PLK1/NRP1 inhibitors holds great therapeutic promise. In this study, five compounds (PLN 1-5) targeting both PLK1 and NRP1 were identified using a multi-step virtual screening approach. PLN-5 showed nanomolar inhibitory potency against PLK1 (IC

Indexed as

Antineoplastic AgentsCell Cycle ProteinsHigh-Throughput Screening AssaysNeuropilin-1Protein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene ProteinsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Dynamics SimulationMolecular StructurePolo-Like Kinase 1Structure-Activity RelationshipAntineoplastic AgentsCell Cycle ProteinsNeuropilin-1NRP1 protein, humanPolo-Like Kinase 1Protein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteinsdual-targeting inhibitorslung cancerneuropilin-1Polo-like kinase-1virtual screening

Identifiers

PMID40820676
PMCPMC12364115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.